Based on our surprising finding that β-catenin upregulates Tim-3 in cDC1s, we aimed to determine whether β-catenin in DCs inhibits anti-tumor CD8 T cell responses through Tim-3 and whether combining Tim-3 blockade ICB with DC vaccines improves the anti-tumor efficacy of DC vaccines. Here, CD8A is linked to neoplasm.